Effects of sodium tanshinone IIA sulfonate against Marek's disease virus in experimentally infected chickens.

Chickens experimentally infected with Marek's disease virus J-1 strain were used to evaluate the anti-Marek's disease virus (MDV) activity of sodium tanshinone IIA sulfonate (STS) in vivo. Chickens in same group were kept in one pen and control group chickens were housed in negative pressure isolator. Chickens were treated with different dose of STS or ABOB for 21 consecutive days. Peripheral T lymphocyte proliferation, expression level of IFN-γ and IL-10 in serum, and MDV load in spleen were determined. The results showed that the treatments with STS and ABOB could significantly increase stimulating index (SI) of peripheral T lymphocytes while the SI is dropping due to the MDV infection, SI of chickens in STS prevention groups were significantly higher than that in STS treatment group and ABOB group (P<0.05 or P<0.01); IFN-γ and IL-10 level of chickens in STS groups were higher than that in other groups (P<0.05 or P<0.01). The results of qPCR demonstrated that STS could inhibit the virus replication in spleen of chickens infected with MDV. These findings indicated that STS can be potentially applied as an anti-MDV drug and set a solid basis for further investigating the antiviral mechanisms of STS.

Therapeutic effects of astragalus polysaccharides on inflammation and synovial apoptosis in rats with adjuvant-induced arthritis.

BACKGROUND: Rheumatoid arthritis (RA), an autoimmune disease, is characterized by pronounced inflammation and cell accumulation within affected joints. Beneficial effects of active ingredients of the astragalus root (Radix astrogali) in treatment of immunological diseases have been previously observed, but the mechanisms are not well understood. This study aims to evaluate therapeutic effects and the mechanisms of astragalus polysaccharides (APS) on adjuvant-induced arthritis (AA) in rats. METHODS: Effects of treatment of AA rats with increasing doses of APS, Tripterygium glycosides (positive control) and saline (negative control) on swelling, arthritic index, synovial cell accumulation, serum concentrations of tumor necrosis factor α (TNF-α) and interleukin-1ß (IL-1ß), synovial apoptosis and immunostaining for Bcl-2 and Bax were determined. RESULTS: APS treatment reduced cell accumulation, swelling and arthritic index of the joints and serum concentrations of TNF-α and IL1-ß in a dose-dependent manner in AA rats. Synovial cell apoptosis was elevated in response to APS treatment and accompanied by increased staining for pro-apoptotic Bax protein and decreased staining for anti-apoptotic Bcl-2 protein. CONCLUSIONS: APS treatment reduced multiple indices of arthritis in rats with AA. Results support further investigation of therapeutic effects of APS in treatment of RA and other autoimmune diseases.